ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT01147991)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 4Immunity, active
Human herpesvirus 4 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01147991 | Phase 1 | Mar 1, 2005 | Cancer Research UK, University of Birmingham |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1